Suggested Dosing
Cognitive impairment due to vascular disease
5-10 mg PO TID
Take with food
Suggested Uses
Increases cerebral blood flow and metabolism, anticonvulsation, cognition enhancement, neuroprotection, antioxidation, cerebral vasodilation
Efficacy
Some clinical studies show prophylactic effects in ischemic stroke & cognitive improvement
Sold as a legal pharmaceutical product in Japan, Europe, & Mexico
Not beneficial in Alzheimer's disease
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Contraindicated (0)
Serious - Use Alternative (0)
Monitor Closely (0)
Minor (15)
- alprazolam
alprazolam increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
- chlordiazepoxide
chlordiazepoxide increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
- clonazepam
clonazepam increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
- clorazepate
clorazepate increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
- diazepam
diazepam increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
- estazolam
estazolam increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
- flurazepam
flurazepam increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
- loprazolam
loprazolam increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
- lorazepam
lorazepam increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
- lormetazepam
lormetazepam increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
- midazolam
midazolam increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
- oxazepam
oxazepam increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
- quazepam
quazepam increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
- temazepam
temazepam increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
- triazolam
triazolam increases effects of vinpocetine by unspecified interaction mechanism. Minor/Significance Unknown. Desirable interaction enhanced memory improvement (based on preliminary trial).
Adverse Effects
Frequency Not Defined
Nausea
Dizziness
Insomnia
Drowsiness
Dry mouth
Transient hypotension
Transient tachycardia
Pressure-type headache
Facial flushing
Prolonged use: slight reductions in both systolic & diastolic blood pressure & blood glucose
Warnings
Contraindications
Hypersensitivity to vinpocetine or other vinca alkaloids
Pts in incomplete homeostasis after cerebral haemorrhage
Pregnancy, lactation
<18 years old
Cautions
Hemophilia, heart problems or low blood pressure
Monitor INR in patients on warfarin
Pregnancy & Lactation
Pregnancy Category: avoid
Lactation: avoid
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Peak Plasma Time: 1-1.5 hr
Half-Life, elimination: 1-2 hr
Absorption: 60% with food, 7% without
Metabolism: extensively to inactive apovincaminic acid in liver
Excretion: urine
Mechanism of Action
Shown to inhibit cGMP phosphodiesterase that has may result in increased cerebral blood flow
Reported to have calcium-channel blocker, voltage-gated sodium channel blocker, & acetylcholine release activities